Medova, Michaela

Up a level
Export as [feed] RSS
Group by: Date | Item Type | Refereed | No Grouping
Jump to: 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2010 | 2009 | 2008

2017

Francica, Paola; Aebersold, Daniel; Medova, Michaela (2017). Senescence as biologic endpoint following pharmacological targeting of receptor tyrosine kinases in cancer. Biochemical pharmacology, 126, pp. 1-12. Elsevier 10.1016/j.bcp.2016.08.022

2016

Francica, Paola; Nisa Hernandez, Lluis; Aebersold, Daniel; Langer, Rupert; Bladt, Friedhelm; Blaukat, Andree; Keogh-Stroka, Deborah M.; Martínez, María Rodríguez; Zimmer, Yitzhak; Medova, Michaela (2016). Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric Cancer. Clinical cancer research, 22(21), pp. 5322-5336. Association for Cancer Research 10.1158/1078-0432.CCR-15-2987

Medova, Michaela (2016). Tepotinib. Selective MET receptor tyrosine kinase inhibitor, Treatment of lung and liver cancers. Drugs of the Future, 41(11), p. 659. Prous Science 10.1358/dof.2016.041.11.2555984

2015

Mikami, K.; Medova, Michaela; Nisa Hernandez, Lluis; Francica, Paola; Glück, Astrid Andreina; Tschan, M.; Blaukat, A.; Bladt, F.; Aebersold, Daniel; Zimmer, Yitzhak (2015). Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition-Associated Checkpoint Abrogation. Molecular cancer research, 13(12), pp. 1544-1553. American Association for Cancer Research AACR 10.1158/1541-7786.MCR-15-0022

Leiser, Dominic; Medova, Michaela; Mikami, Kei; Nisa Hernandez, Lluis; Keogh-Stroka, Deborah M.; Blaukat, Andree; Bladt, Friedhelm; Aebersold, Daniel; Zimmer, Yitzhak (2015). KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells. Molecular oncology, 9(7), pp. 1434-1446. Elsevier 10.1016/j.molonc.2015.04.001

Piguet, Anne-Christine; Medova, Michaela; Keogh, Adrian; Glück, Astrid Andreina; Aebersold, Daniel; Dufour, Jean-François; Dufour, Jean-François; Zimmer, Yitzhak (2015). Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer. Genes & cancer, 6(7-8), pp. 317-327. Impact Journals

Glück, Astrid Andreina; Aebersold, Daniel; Zimmer, Yitzhak; Medova, Michaela (2015). Interplay between receptor tyrosine kinases and hypoxia signaling in cancer. The international journal of biochemistry & cell biology, 62, pp. 101-114. 10.1016/j.biocel.2015.02.018

Nisa Hernandez, Lluis; Aebersold, Daniel; Giger, Roland; Caversaccio, Marco; Borner, Urs; Medova, Michaela; Zimmer, Yitzhak (2015). Profiling invasiveness in head and neck cancer: recent contributions of genomic and transcriptomic approaches. Cancers, 7(2), pp. 585-597. MDPI AG 10.3390/cancers7020585

2014

Nisa Hernandez, Lluis; Aebersold, Daniel; Giger, Roland; Zimmer, Yitzhak; Medova, Michaela (2014). Biological, diagnostic and therapeutic relevance of the MET receptor signaling in head and neck cancer. Pharmacology & therapeutics, 143(3), pp. 337-349. Elsevier 10.1016/j.pharmthera.2014.04.005

Leiser, Dominic; Pochon, Benoît; Blank Wieslawa, Elzbieta; Francica, Paola; Glück, Astrid; Aebersold, Daniel; Zimmer, Yitzhak; Medova, Michaela (2014). Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation. FEBS letters, 588(5), pp. 653-658. Elsevier 10.1016/j.febslet.2013.12.025

Medova, Michaela; Aebersold, Daniel M.; Zimmer, Yitzhak (2014). The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response - Biological and Clinical Aspects. Cancers, 6(1), pp. 1-27. MDPI AG 10.3390/cancers6010001

2013

Medová, Michaela; Pochon, Benoît; Streit, Bruno; Blank-Liss, Wieslawa; Francica, Paola; Stroka, Deborah; Keogh, Adrian; Aebersold, Daniel M.; Blaukat, Andree; Bladt, Friedhelm; Zimmer, Yitzhak (2013). The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants. Molecular cancer therapeutics, 12(11), pp. 2415-2424. American Association for Cancer Research AACR 10.1158/1535-7163.MCT-13-0151

Humbert, Magali; Medova, Michaela; Aebersold, Daniel; Blaukat, Andree; Bladt, Friedhelm; Fey, Martin; Zimmer, Yitzhak; Tschan, Mario P. (2013). Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells. Biochemical and biophysical research communications, 431(2), pp. 264-269. Academic Press 10.1016/j.bbrc.2012.12.120

2012

Medová, Michaela; Aebersold, Daniel M; Zimmer, Yitzhak (2012). MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks. International journal of cancer, 130(3), pp. 728-34. Malden, Mass.: Wiley-Blackwell 10.1002/ijc.26058

2010

Zimmer, Yitzhak; Vaseva, Angelina V; Medová, Michaela; Streit, Bruno; Blank-Liss, Wieslawa; Greiner, Richard H; Schiering, Nikolaus; Aebersold, Daniel M (2010). Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274. Cancer letters, 289(2), pp. 228-36. Amsterdam: Elsevier 10.1016/j.canlet.2009.08.017

2009

Banz, Vanessa M; Medová, Michaela; Keogh, Adrian; Furer, Cynthia; Zimmer, Yitzhak; Candinas, Daniel; Stroka, Deborah (2009). Hsp90 transcriptionally and post-translationally regulates the expression of NDRG1 and maintains the stability of its modifying kinase GSK3beta. Biochimica et biophysica acta - molecular cell research, 1793(10), pp. 1597-603. New York, N.Y.: Elsevier 10.1016/j.bbamcr.2009.08.002

2008

Ganapathipillai, Suganthini S; Medová, Michaela; Aebersold, Daniel M; Manley, Paul W; Berthou, Sylvie; Streit, Bruno; Blank-Liss, Wieslawa; Greiner, Richard H; Rothen-Rutishauser, Barbara; Zimmer, Yitzhak (2008). Coupling of mutated Met variants to DNA repair via Abl and Rad51. Cancer research, 68(14), pp. 5769-77. Birmingham, Ala.: American Association for Cancer Research AACR 10.1158/0008-5472.CAN-08-1269

Provide Feedback